Sinus Cocktail Injection Dosing
There is no established evidence-based guideline for "sinus cocktail" injections combining dexamethasone and diphenhydramine for sinusitis, and this practice lacks support in current clinical practice guidelines.
Critical Context
The term "sinus cocktail" typically refers to off-label combinations used in some clinical settings for acute symptom relief in sinusitis. However, the 2025 Adult Sinusitis Clinical Practice Guideline does not recommend injectable corticosteroid-antihistamine combinations for acute bacterial rhinosinusitis (ABRS) 1.
Evidence-Based Dosing from Related Clinical Contexts
Diphenhydramine (Benadryl) Dosing
Based on FDA labeling and allergy management guidelines:
The FDA label confirms diphenhydramine injectable is indicated for allergic reactions when oral therapy is impractical, but does not specify sinusitis as an indication 3.
Dexamethasone (Decadron) Dosing
Based on FDA labeling and clinical literature:
- Adults: 4-8 mg IV/IM is commonly used in various inflammatory conditions 4, 5, 6
- Pediatrics: Dosing varies widely (0.75-9 mg daily) and must be individualized based on disease severity 7
For anaphylaxis management (where both drugs are used together), guidelines recommend dexamethasone at 1.0-2.0 mg/kg/day IV divided every 6 hours, though this is for severe systemic reactions, not sinusitis 2.
Compatibility and Stability
Research confirms that dexamethasone and diphenhydramine are physically compatible when mixed, but only within specific concentration ranges 8. An admixture containing diphenhydramine 2 mg/mL and dexamethasone 0.16 mg/mL in normal saline remained stable for 48 hours at room temperature 9.
Clinical Caveats and Recommendations
The 2025 sinusitis guideline does not support systemic corticosteroid monotherapy for ABRS 1. A Cochrane review found no benefit for oral steroids as monotherapy, with only modest short-term benefit when combined with antibiotics (NNT=7), but with significant risk of attrition bias 1.
Intranasal corticosteroids are the evidence-based approach for ABRS as adjunctive therapy, not injectable combinations 1. Topical therapy avoids systemic adverse effects while providing local anti-inflammatory benefits.
If this injection is being considered despite lack of guideline support, the most commonly referenced doses from related literature would be:
- Diphenhydramine 25-50 mg IM (adults) or 1-2 mg/kg IM (pediatrics, max 50 mg) 2
- Dexamethasone 4-8 mg IM (adults) 4, 5, 6
Major concerns with this approach:
- No RCT evidence supports injectable corticosteroid-antihistamine combinations for sinusitis 1
- Systemic corticosteroids carry risks including hyperglycemia, immunosuppression, and HPA axis suppression 2
- Even short-term intranasal dexamethasone in infants has caused iatrogenic Cushing's syndrome 10
- Antihistamines have no role in non-atopic patients with ABRS and may worsen congestion by drying nasal mucosa 1